Transfer Factor-a New Form for Immunotherapy
نویسندگان
چکیده
منابع مشابه
a new approach to credibility premium for zero-inflated poisson models for panel data
هدف اصلی از این تحقیق به دست آوردن و مقایسه حق بیمه باورمندی در مدل های شمارشی گزارش نشده برای داده های طولی می باشد. در این تحقیق حق بیمه های پبش گویی بر اساس توابع ضرر مربع خطا و نمایی محاسبه شده و با هم مقایسه می شود. تمایل به گرفتن پاداش و جایزه یکی از دلایل مهم برای گزارش ندادن تصادفات می باشد و افراد برای استفاده از تخفیف اغلب از گزارش تصادفات با هزینه پائین خودداری می کنند، در این تحقیق ...
15 صفحه اولDesigning a New Form Factor for Wearable Computing
W earable computers have more to do with form factor and usability than with computing.1,2 Aside from a few early adopters who might be eager to experiment, most potential users are primarily interested in what a wearable device can do for them. These potential users must be convinced that the benefits of wearing the device outweigh the difficulty involved in carrying or caring for it. You can ...
متن کاملA New Piecewise EOS for Compressibility Factor Prediction Based on the M-factor Theory
In this study for the first time a new description of compressibility factor is rendered based on the virial expansion. The compressibility factor as a function of M-factor is qualitatively and quantitatively expressed. At first, we present how may the third, fourth and higher order virial coefficients be logically ignored in order to simplify the virial equation. The results show, wh...
متن کاملImmunotherapy with Dialyzable Leukocyte Extracts Containing Transfer Factor
Dialyzable leukocyte extracts (DLE) are complexes consisting of a large number of low molecular weight substances. These extracts possess immunomodulatory properties, which are mainly attributed to small peptides with molecular weight of 3.5–6.0 kDa called “transfer factor.” This chapter reviews the nature and immunological characteristics of DLE containing transfer factor (TF), their mechanism...
متن کاملImmunotherapy with transfer factor of recurrent herpes simplex type I.
This clinical trial of Transfer Factor, an immunomodulator, in the treatment of herpes simplex type I, proved this agent to be more effective as regards duration of acute phase recurrences as well as the frequency of the reappearance of relapses of this disease. The evaluation was made in 20 patients whose disease had been treated before with other therapeutic agents (including acyclovir) which...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Acta Medica Scandinavica
سال: 2009
ISSN: 0001-6101
DOI: 10.1111/j.0954-6820.1975.tb19498.x